Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood clues may predict heart trouble after stent

NCT ID NCT00725868

Knowledge-focused Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checked if certain blood markers can predict serious heart events like heart attack or death within a year after a stent procedure. Researchers measured two types of cells related to blood vessel health in 170 adults scheduled for a stent. The goal was to see if these markers could help doctors identify patients at higher risk for complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

170 people

The number who actually took part.

Start date

Sep 2007

Finished

Dec 2010

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age\>18 years old * Scheduled for PCI * Clinical evidence of ischemic heart disease and/or abnormal functional study * New coronary artery lesion \>50% * treatment with bare metal stent planned * Informed consent explained, red, understood and signed by the patient Exclusion Criteria: * Pregnancy, birth or lactation period \<6 months ago * Women of childbearing age who do not intend to use accepted anticonceptive measures or who wish to get pregnant * Left ventricular ejection fraction \<30% * Acute coronary syndrome (ST-elevation or not) in the past month * Planned drug eluting stent implantation * Lesion in arterial or venous bypass or anastomosis with coronary * Severe renal insufficiency (creatinine clearance \<30 mL/') * Severe hepatic insufficiency * Systemic inflammatory pathology of any kind * Hematologic or other malignancy, prior radio- or chemotherapy * Use of corticosteroïds or immune suppression therapy * Contrast allergy * Life expectancy \<1 year * Participation in other clinical study which has not ended yet

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular disorder coronary artery disorder myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis Cardiovascular diseases Percutaneous coronary intervention

Contacts and locations

Locations

  • Service de Cardiologie- Hopital Nord

    Marseille, 13015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.